natgillin/translations-raw huggingface dataset:
If UPC ratio > 2, or creatinine > 1.5 upper limit of normal (ULN), or albumin < 0.75 lower limit of normal (LLN) or blood urea nitrogen (BUN) > 1.5 ULN, discontinue treatment. 
Ako je omjer UPC > 2, ili je kreatinin > 1.5 gornje granice normale (GGN), ili albumin < 0.75 donje granice normale (DGN) ili ureja u krvi (blood urea nitrogen - BUN) > 1.5 GGN, liječenje treba prekinuti.
In case of adverse events following overdose, treatment should be discontinued until resolution, and then resumed at the recommended therapeutic dose level. 
U slučaju nastajanja nuspojava radi predoziranja, liječenje treba prekinuti do prestanka istih, a potom nastaviti liječenje primjenom preporučene terapijske doze.
Dogs should be monitored carefully and professional judgement should be used to determine the need for dose reduction in the event of possible significant adverse reactions. 
Pse treba pažljivo nadzirati te na osnovi stručne procijene treba odlučiti potrebu za smanjenjem doze u slučaju mogućih značajnih nuspojava.
Repeated dermal contact with masitinib may impair female fertility and foetal development. 
Ponavljani kontakt masitiba s kožom može utjecati na plodnost ženki i razvoj ploda.
The treatment should be discontinued if any of these signs are observed: anaemia, severe neutropenia, severe renal toxicity, hepatic toxicity and/or severe diarrhoea or vomiting persistent after dose reduction. 
Liječenje treba prekinuti ako se primjeti bilo koji od ovih znakova: anemija, teška neutropenija, teška intoksikacija bubrega, intoksikacija jetre i/ili teški proljev ili povraćanje koji ne nestaju i nakon smanjenja doze.
Dogs should not be used for breeding while under treatment. 
Za vrijeme liječenja psi se nesmiju upotrebljavati za rasplod.
• If broken tablets, vomit, urine or faeces of treated dogs come into contact with the skin, rinse immediately with plenty of water. 
• Ukoliko slomljena tableta, povraćeni sadržaj, mokraća ili izmet dođu u kontakt s kožom, odmah isprati s puno vode.
Special precautions for use in animals: What are the special precautions for my dog? 
Koje su posebne mjere opreza za mog psa?
If a broken tablet is rejected by the dog after chewing, it should be disposed of. 
Ako pas ispljune dio tablete nakon žvakanja, taj dio treba baciti.
Each tablet contains either 50 mg or 150 mg of masitinib, which is the active substance. 
Svaka tableta sadrži 50 mg ili 150 mg djelatne tvari masitinib.
> 3 ULN 
> 3 GGN
Masivet is a prescription medicine used to treat dog mast cell tumours. 
Masivet je VMP koji se izdaje na recept koji se koristi za liječenje tumora mastocita u pasa.
3 avenue George V 75008 Paris 
3 avenue George V 75008 Pariz
Increase in aminotransferase (ALT or AST) with a mean duration of approximately 29 days. 
Porast aminotransferaze (ALT ili AST) s prosječnim trajanjem od oko 29 dana.
Haemoglobin < 10 g/dl and either free bilirubin > 1.5 ULN and haptoglobin < 0.1 g/dl or reticulocytes < 80,000/mm 
Hemoglobin < 10 g/dl i slobodni bilirubin > 1.5 GGN i haptoglobin< 0.1 g/dl ili retikulociti < 80.000/mm
Concurrent use of other substances with a high degree of protein binding may compete with masitinib binding and thus cause adverse effects. 
Istodobna primjena drugih tvari s visokim stupnjem vezivanja za bjelančevine može konkurirati vezivanjumasitiniba i tako izazvati nuspojave.
THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable 
13. RIJEČI “ SAMO ZA PRIMJENU NA ŽIVOTINJAMA ” I UVETI ILI OGRANIČENJA
The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch. 
Na uputi o VMP se mora nalaziti naziv i adresa proizvođača odgovornog za puštanje dotične serije.
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician. 
U slučaju da se nehotice proguta odmah potražiti pomoć liječnika i pokažite mu uputu o VMP ili etiketu.
Lipoma (mean duration 53 days). 
Lipom (prosječno trajanje 53 dana).
BATCH NUMBER 
SERIJSKI BROJ
In the case of adverse reactions, doses might be reduced to once daily doses of 9 mg/kg bodyweight (range 7.5-10.5 mg/kg) or 6 mg/kg bw (range 4.5-7.5 mg/kg) according to the tables below. 
U slučaju nuspojava, doze se mogu smanjiti na jednodnevne doze od 9 mg/kg tjelesne težine (raspon 7.5 - 10.5 mg/kg) ili 6 mg/kg tjelesne težine (raspon 4.5 - 7.5mg/kg) prema tablicama u nastavku.
Treatment should be discontinued in case of: Haemolytic anaemia, i.e. haemoglobin < 10 g/dl and haemolysis, i.e. free bilirubin > 1.5 ULN and haptoglobin < 0.1 g/dl, Anaemia due to lack of regeneration, i.e. haemoglobin< 10 g/dl and reticulocytes < 80,000/mm 
Liječenje treba prekinuti u slučaju: hemolitičke anemije, tj. ako je hemoglobin < 10 g/dl, te hemolize, tj. ako je slobodni bilirubin > 1.5 GGN i haptoglobin < 0.1 g/dl, anemije uzrokovane nedostatkom regeneracije, tj. ako je hemoglobin < 10 g/dl i ako su retikulociti < 80.000/mm
Lymphadenopathy (mean duration 47 days). 
Limfadenopatija (prosječno trajanje 47 dana).
Decrease in appetite or anorexia with a mean duration of 45 days and 18 days, respectively. 
Smanjenje apetita ili anoreksija s prosječnim trajanjem od oko 45 dana, odnosno 18 dana.
ADVERSE REACTIONS Should I expect side effects for my dog during Masivet therapy? 
NUSPOJAVE Trebam li očekivati nuspojave u mog psa tijekom liječenja Masivetom?
In case of tumour progression, efficacy of treatment is unlikely to be successful and the treatment should be reviewed. 
U slučaju progresije tumora, učinkovitost liječenja nije izgledna, te liječenje treba preispitati.
Can other medications be given while my dog is taking Masivet? 
Mogu li se drugi VMP davati psu dok dobiva Masivet?
Mild to moderate hair loss with a mean duration of approximately 26 days. 
Blagi do umjereni gubitak dlake s prosječnim trajanjem od oko 26 dana.
9 mg per kg bodyweight once daily as presented in the table below. 
9 mg po kg tjelesne težine dnevno kao što je prikazano u donjoj tablici.
• Wear protective gloves while disposing of vomit, urine or faeces of treated dogs. 
• Nositi zaštitne rukavice kod rukovanja povraćenim sadržajem, mokraćom ili izmetom liječenih pasa.
In case of tumour progression, treatment is unlikely to be successful and the treatment should be reviewed. 
U slučaju progresije tumora, liječenje vjerojatno neće biti uspješno te ga treba preispitati.
Cough (mean duration 23 days). 
Kašalj (prosječno trajanje 23 dana).
Mild or moderate neutropenia with a mean duration of approximately 24 days. 
Blaga ili umjerena neutropenija s prosječnim trajanjem od oko 24 dana.
Albumin < 1 LLN or UPC > 2 
Albumin < 1 DGN ili UPC > 2
In case of positive semiquantitative dipstick results (protein > 30 mg/dl), urinalysis should be performed to determine urinary protein creatinine (UPC) ratio, and a blood sample to measure creatinine, albumin and BUN. 
U slučaju pozitivnih polukvantitativnih rezultata mjerenja papirnom trakom (bjelančevine > 30 mg/dl), treba provesti analizu mokraće kako bi se utvrdio omjer bjelančevina i kreatinina u mokraći (UPC), te uzeti uzorak krvi za mjerenje kreatinina, albumina i ureje u krvi.
Mild to moderate alopecia with a mean duration of approximately 26 days. 
Blaga do umjerena alopecija s prosječnim trajanjem od oko 26 dana.
Do not use in dogs suffering from renal function impairment, defined as Urinary Protein Creatinine (UPC) ratio > 2 or albumin < 1 x Lower Limit of Normal (LLN). 
Ne primjenjivati na psima koji koji imaju oštećenje bubrežne funkcije, definirano kao porast omjer bjelančevina i kreatinina u mokraći (Urinary Protein Creatinine - UPC ratio) > 2 ili pad albumina < 1
6 mg per kg bodyweight once daily as presented in the table below. 
6 mg po kg tjelesne težine dnevno kao što je prikazano u donjoj tablici.
Do not use in pregnant or lactating bitches. 
Ne primjenjivati u gravidnih kuja ili kuja u laktaciji.
At the second occurrence of the same event, treatment should be interrupted until resolution; treatment should then be continued with a reduced dose of 9 mg/kg bodyweight/day; At the third occurrence of the same event, treatment should be interrupted until resolution; treatment should then be continued with a dose further reduced to 6 mg/kg/day; Treatment should be discontinued, if severe adverse reactions are still encountered at the 6 mg/kg/day dose. 
Kod drugog pojavljivanja iste nuspojave, liječenje treba prekinuti do prestanka iste; liječenje treba nastaviti smanjenom dozom od 9 mg/kg tjelesne težine/dan;
• Avoid skin contact with faeces, urine, and vomit of treated dogs. 
• Izbjegavati kontakt kože sa izmetom, mokraćom i povraćenim sadržajem liječenih pasa.
Tablet coating: 
Obloga tablete:
Mild to moderate gastrointestinal reactions (diarrhoea and vomiting) with a mean duration of approximately 21 and 9 days, respectively. 
Blage do umjerene želučanocrijevne reakcije (proljev i povraćanje) s prosječnim trajanjem od oko 21 odnosno 9 dana.
Hepatic toxicity (ALT or AST elevation), neutropenia In case of an increase of ALT or AST > 3 ULN, decrease of neutrophil count < 2,000/mm or any other severe adverse events, treatment should be modified as follows: At the first occurrence, treatment should be interrupted until resolution, and then resumed at the same dose level; 
Intoksikacija jetre (porast ALT ili AST), neutropenija U slučaju povećanja ALT ili AST > 3 GGN, pada broja neutrofila < 2000/mm ili bilo koje druge teške nuspojave, liječenje treba izmijeniti kako slijedi:
Moderate to severe anaemia (aplastic/haemolytic) with a mean duration of approximately 7 days. 
Umjerena do teška anemija (aplastična/hemolitička) s prosječnim trajanjem od oko 7 dana.
• is less 6 months of age or weights less than 4 kg, 
• je mlađi od 6 mjeseci ili teži manje od 4 kg, pati od neadekvatne jetrene ili bubrežne funkcije
Monitoring of Protein loss syndrome Perform every month a dipstick urine test. 
Praćenje sindroma gubitka bjelančevina Svaki mjesec treba napraviti kontrolu mokraće testnom trakom.
Do not use in dogs with neutropenia defined as absolute neutrophil count < 2,000 /mm Do not use in case of hypersensitivity to the active substance or to any of the excipients. 
Ne primjenjivati napsima s neutropenijom ako je ukupni broj neutrofila < 2.000 /mm
AB Science S.A. 3 avenue George V FR-75008 Paris France 
AB Science S.A. 3 avenue George V FR-75008 Pariz Francuska
Treatment of non-resectable dog mast cell tumours (Grade 2 or 3) with confirmed mutated c-kit tyrosine kinase receptor. 
Liječenje neoperabilnog tumora mastocita u pasa (stupanj 2 ili 3) s potvrđenom mutacijom receptora c-kit tirozin kinaze.
In case of positive semi-quantitative dipstick results (protein ≥ 30 mg/dl), perform urinalysis to determine urinary protein creatinine (UPC) ratio. 
U slučaju pozitivnih rezultata testiranja s polukvantitativnim testnim trakama (bjelančevine ≥ 30 mg / dl), treba provesti analizu mokraće kako bi se utvrdio omjer bjelančevina i kreatinina u mokraći (UPC).
Manufacturer for batch release: 
Nositelj odobrenja za proizvodnju za puštanje proizvodne serije:
60 ml bottle containing 30 Masivet 150 mg film-coated tablets. 
Bočica od 60 ml sadrži 30 Masivet filmom obloženih tableta od 150 mg.
12.5 mg/kg bw Number of tablets per day 
12.5 mg/kg tjelesne težine
40 ml bottle containing 30 Masivet 50 mg film-coated tablets. 
Bočica od 40 ml sadrži 30 Masivet filmom obloženih tableta od 50 mg.
Masivet is for the treatment of dogs with non-resectable mast cell tumours (Grade 2 or 3) with a confirmed mutated c-kit tyrosine kinase receptor. 
Masivet se koristi za liječenje pasa s neoperabilnim tumorom mastocita ( stupanj 2 ili 3), s potvrđenim mutiranim receptorom tirozin kinaza c-kit.
Doses can be reduced to 9 mg/kg bodyweight (range 7.5-10.5 mg/kg) or 6 mg/kg bw (range 4.5-7.5 mg/kg) according to the tables below. 
5 mg/kg) ili na 6 mg/kg tjelesne težine (raspon 4.5 - 7.5 mg/kg) u skladu s tablicama u nastavku.
Oedema (mean duration of oedema was 7 days). 
Edem (prosječno trajanje 7 dana).
6 mg per kg bodyweight 
6 mg po kg tjelesne težine
MASIVET 50 mg film-coated tablets for dogs MASIVET 150 mg film-coated tablets for dogs 
MASIVET 50 mg filmom obložene tablete za pse MASIVET 150 mg filmom obložene tablete za pse
Very common effects: 
Česti učinci
Albumin < 0.75 LLN or UPC > 2 
Albumin < 0.75 DGN ili UPC > 2 (2. put)
9 mg per kg bodyweight 
9 mg po kg tjelesne težine
Masitinib treatment should only be used in dogs with non-resectable mast cell tumours and which express the mutated c-kit tyrosine kinase receptor. 
Liječenje masitinibom treba koristiti samo u pasa s neoperabilnim tumorom mastocita i u onih s izraženom mutacijom receptora c-kit tirozin kinaze.
6.2 Incompatibilities 
Nekompatibilnosti
Management of Haemolytic and aregenerative Anaemia (haemoglobin, bilirubin, haptoglobin, reticulocytes) 
(hemoglobin, bilirubin, haptoglobin, retikulociti) Kontraindikacija Prekid doziranja Smanjenje doze
• is pregnant or nursing puppies, 
• je skotna ili doji,
MASIVET 50 mg film-coated tablets for dogs Masitinib 
MASIVET 50 mg filmom obložena tableta za pse Masitinib
PACKAGE LEAFLET MASIVET 50 mg film-coated tablets for dogs MASIVET 150 mg film-coated tablets for dogs 
UPUTA O VMP MASIVET 50 mg filmom obložene tablete za pse MASIVET 150 mg filmom obložene tablete za pse
MASIVET 150 mg film-coated tablets for dogs Masitinib 
MASIVET 150 mg filmom obložene tablete za pse Masitinib
EXPIRY DATE 
DATUM ISTEKA VALJANOSTI
< 2,000/mm st time) 
< 2.000/mm (4. put)
Masitinib treatment should only be used in dogs with non-resectable mast cell tumours, which express the mutated c-kit tyrosine kinase receptor. 
Masitinib se smije koristiti samo u liječenju pasa s neoperabilnim tumorima mastocita koj imaju mutirani receptorc-kit tirozin kinaze.
< 2,000/mm th time) 
< 2.000/mm (1. put)
Excipients. 
OBLIK
Excretion takes place in the bile. 
Izlučuje se putem žuči.
This summary was last updated in 06-2017. 
Ovaj je sažetak posljednji put ažuriran u 06. 2017.
Doses can be increased further until the most effective dose is reached. 
Doze se mogu povećavati sve dok se ne dosegne najdjelotvornija doza.
Pregabalin Accord is available as capsules (25, 50, 75, 100, 150, 200, 225 and 300 mg) and can only be obtained with a prescription. 
Lijek Pregabalin Accord dostupan je u kapsulama (25, 50, 75, 100, 150, 200, 225 i 300 mg), a izdaje se samo na liječnički recept.
The full EPAR for Pregabalin Accord can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Cjeloviti EPAR za lijek Pregabalin Accord nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
To stop treatment with Pregabalin Accord, the dose should be reduced gradually, over at least a week. 
Da bi se terapija lijekom Pregabalin Accord prekinula dozu treba postupno smanjivati, tijekom najmanje jednog tjedna.
After one week, the dose can be increased to 300 mg per day. 
Nakon tjedan dana doza se može povećati na 300 mg na dan.
This reduces the activity of some of the nerve cells in the brain and spinal cord, reducing the release of other neurotransmitters that are involved in epilepsy and anxiety. 
Time se smanjuje aktivnost pojedinih živčanih stanica u mozgu i kralježničnoj moždini, čime se smanjuje otpuštanje drugih neurotransmitera koji su uključeni u epilepsiju i anksioznost.
Pregabalin Accord is a medicine used to treat adults with the following conditions: 
Pregabalin Accord je lijek koji se koristi za liječenje odraslih osoba sa sljedećim bolestima:
• generalised anxiety disorder (long-term anxiety or nervousness about everyday matters). 
• generaliziranim anksioznim poremećajem (kroničnom anksioznosti ili nervozom vezanom uz svakodnevnicu).
• epilepsy, where it is used as an ‘add-on' to other epilepsy treatment in patients who have partial seizures (epileptic fits starting in one specific part of the brain); 
• epilepsijom, kada se koristi kao dodatna terapija uz druge terapije za liječenje epilepsije u bolesnika koji imaju parcijalne napadaje (epileptične napadaje koji izbijaju u jednom specifičnom djelu mozga);
This means that Pregabalin Accord contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the European Union (EU) called Lyrica. 
To znači da Pregabalin Accord sadrži istu djelatnu tvar i djeluje na isti način kao i „referentni lijek” koji je već odobren u Europskoj uniji (EU) pod nazivom Lyrica.
The exact way in which pregabalin works is not fully understood, but it is thought to affect the way that calcium enters nerve cells. 
Nije u potpunosti poznat način na koji pregabalin djeluje, no smatra se da utječe na način na koji kalcij ulazi u živčane stanice.
What is Pregabalin Accord and what is it used for? 
Što je Pregabalin Accord i za što se koristi?
• neuropathic pain (pain due to nerve damage), including peripheral neuropathic pain, such as the pain experienced by patients with diabetes or herpes zoster (shingles), and central neuropathic pain, such as the pain experienced by patients who have had a spinal cord injury; 
• neuropatskom boli (boli uslijed oštećenja živca), uključujući perifernu neuropatsku bol, poput boli koju iskuse bolesnici oboljeli od dijabetesa ili herpes zosterom (pasac), i središnjom neuropatskom boli, poput boli koju osjete bolesnici koji imaju ozljedu kralježnične moždine;
As for every medicine, the company provided studies on the quality of Pregabalin Accord. 
Kao i za svaki lijek, tvrtka je dostavila ispitivanja o kvaliteti lijeka Pregabalin Accord.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Pregabalin Accord has been shown to have comparable quality and to be bioequivalent to Lyrica. 
Odbor za lijekove za humanu uporabu (CHMP) pri Agenciji zaključio je kako je, u skladu sa zahtjevima EU-a, potvrđeno da Pregabalin Accord posjeduje usporedivu razinu kvalitete i da je bioekvivalentan lijeku Lyrica.
What measures are being taken to ensure the safe and effective use of Pregabalin Accord? 
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Pregabalin Accord?
Studies on the benefits and risks of the active substance in the approved uses have already been carried out with the reference medicine, Lyrica, and do not need to be repeated for Pregabalin Accord. 
Ispitivanja o koristima i rizicima djelatne tvari pri odobrenoj primjeni već su provedena za referentni lijek Lyrica te ih ne treba ponavljati za lijek Pregabalin Accord.
Pregabalin Accord is a ‘generic medicine'. 
Pregabalin Accord je „generički lijek”.
This is a summary of the European public assessment report (EPAR) for Pregabalin Accord. 
Ovo je sažetak europskoga javnog izvješća o procjeni (EPAR) lijeka Pregabalin Accord.
The company also carried out studies that showed that it is ‘bioequivalent' to the reference medicine. 
Tvrtka je provela i ispitivanja koja su pokazala da je lijek „bioekvivalentan” referentnom lijeku.
The active substance in Pregabalin Accord, pregabalin, is similar in structure to the body's own ‘neurotransmitter' gamma‑amino butyric acid (GABA), but has very different biological effects. 
Djelatna tvar lijeka Pregabalin Accord, pregabalin, slična je po strukturi neurotransmiteru tijela, gamaaminobutiričnoj kiselini (GABA), no ima vrlo različito biološko djelovanje.
Because Pregabalin Accord is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's. 
Budući da je Pregabalin Accord generički lijek te je bioekvivalentan referentnom lijeku, smatra se da su njegove koristi i rizici isti kao i oni referentnog lijeka.
The European Commission granted a marketing authorisation valid throughout the European Union for Pregabalin Accord on 28 August 2015. 
Europska komisija izdala je odobrenje za stavljanje lijeka Pregabalin Accord u promet koje vrijedi na prostoru Europske unije od 28. kolovoza 2015.
What are the benefits and risks of Pregabalin Accord? 
Koje su koristi i rizici lijeka Pregabalin Accord?
For more information about treatment with Pregabalin Accord, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Više informacija o liječenju lijekom Pregabalin Accord pročitajte u uputi o lijeku (također dio EPAR-a), odnosno obratite se svojem liječniku ili ljekarniku.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Pregabalin Accord have been included in the summary of product characteristics and the package leaflet. 
Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Pregabalin Accord nalaze se u sažetku opisa svojstava lijeka i u uputi o lijeku.
The Committee recommended that Pregabalin Accord be approved for use in the EU. 
Odbor je preporučio davanje odobrenja za stavljanje lijeka Pregabalin Accord u promet u EU-u.
It is not intended to provide practical advice on how to use Pregabalin Accord. 
Svrha sažetka nije davati praktične savjete o primjeni lijeka Pregabalin Accord.
For practical information about using Pregabalin Accord, patients should read the package leaflet or contact their doctor or pharmacist. 
Praktične informacije o primjeni lijeka Pregabalin Accord bolesnici trebaju pročitati u uputi o lijeku, odnosno trebaju se obratiti svojem liječniku ili ljekarniku.
Other information about Pregabalin Accord 
Ostale informacije o lijeku Pregabalin Accord
Therefore, the CHMP's view was that, as for Lyrica, the benefit outweighs the identified risk. 
Stoga je stav CHMP-a da korist nadmašuje identificirani rizik, kao i za lijek Lyrica.
Pregabalin Accord contains the active substance pregabalin. 
Pregabalin Accord sadrži djelatnu tvar pregabalin.
Why is Pregabalin Accord approved? 
Zašto je lijek Pregabalin Accord odobren?
How does Pregabalin Accord work? 
Kako djeluje Pregabalin Accord?
How has Pregabalin Accord been studied? 
Kako je Pregabalin Accord ispitivan?
How is Pregabalin Accord used? 
Kako se Pregabalin Accord koristi?
448 (8x 56) capsules +10 inhalers (2 x monthly multipack) 
blister (Al/Al) 448 (8x 56) kapsula +10 inhalatora (2 x mjesečno višestruko pakiranje)
224 (4x 56) capsules + 5 inhalers (monthly multipack) 
Veličina pakovanja blister (Al/Al) 56 kapsula + 1 inhalator blister (Al/Al) 224 (4x 56) kapsule + 5 inhalatora (mjesečno višestruko pakiranje)
Do not smoke, eat or drink while handling the product. 
Ne pušiti, jesti i piti dok rukujete ovim proizvodom.
Animals older than six weeks of age: 
Životinje starije od 6 tjedana:
ATC vet code: QP54AA05. 
ATC vet kod: QP54AA05.
Avoid contact between the product and your fingers. 
Izbjegavati dodir proizvoda i prstiju.
On the day of treatment, children must not handle treated animals and the animals should not be permitted to sleep with their owners, especially children. 
Na dan primjene, djeci ne treba dozvoliti da rukuju s tretiranim životinjama, a životinjama ne treba dozvoliti da spavaju s vlasnicima, posebno s djecom.
CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES 
3. SADRŽAJ PO TEŽINI, VOLUMENU ILI BROJU DOZA
Interaction with other medicinal products and other forms of interaction: None known. 
Interakcije s drugim medicinskim proizvodima i drugi oblici interakcija: Nisu poznate.
Appropriate combination of pipettes 
Odgovarajuća kombinacija pipeta
This product is highly flammable; keep away from heat, sparks, open flames or other sources of ignition. 
Ovaj proizvod je jako zapaljiv; držati dalje od izvora topline, iskrenja, otvorenog plamena i drugih izvora zapaljenja.
Αθηνών - Λαμίας, T.K.14452, Μεηαμόρθωζη, Ελλάδα 
13o χλμ Ε.Ο. Αθηνών - Λαμίας, T.K.14452, Μεηαμόρθωζη, Ελλάδα
Each single-dose (pipette) delivers: 
Svaka doza (pipeta) sadržava:
This product is not effective against adult D. immitis. 
Proizvod nije učinkovit protiv odraslih oblika D. immitis.
None known 
Nisu poznate.
06517 Carros France service-conso@virbac.fr 
06517 Carros Francja service-conso@virbac.fr
Colourless to yellow solution. 
Bezbojna do žuta otopina.